ACADIA Pharmaceuticals Inc (ACAD.O) People | Reuters.com
Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

32.38USD
29 Jun 2016
Change (% chg)

$0.72 (+2.27%)
Prev Close
$31.66
Open
$32.04
Day's High
$32.72
Day's Low
$31.61
Volume
1,875,542
Avg. Vol
3,183,171
52-wk High
$51.99
52-wk Low
$16.64

Summary

Name Age Since Current Position

Stephen Biggar

45 2016 Chairman of the Board

Stephen Davis

54 2015 President, Chief Executive Officer, Chief Financial Officer, Director

Glenn Baity

45 2014 Executive Vice President, General Counsel, Secretary

Terrence Moore

60 2013 Executive Vice President, Chief Commercial Officer

Srdjan Stankovic

58 2015 Executive Vice President, Head - Research and Development

Julian Baker

50 2015 Director

James Daly

2016 Director

Edmund Harrigan

56 2015 Director

Laura Brege

58 2008 Independent Director

Daniel Soland

56 2015 Independent Director

Lisa Barthelemy

2015 Director, Investor Relations

Biographies

Name Description

Stephen Biggar

Dr. Stephen R. Biggar, M.D. Ph.D. is Chairman of the Board of Acadia Pharmaceuticals Inc. He is an employee at Baker Brothers Advisors LP, a registered investment adviser focused on long-term investments in life-sciences companies. Dr. Biggar joined Baker Brothers Advisors in 2000. Dr. Biggar also serves as a director for Synageva BioPharma Corp., a publicly traded biotechnology company. The NCG Committee believes that Dr. Biggar’s scientific background and financial industry experience make him a valuable contributor to Board discussions. Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester.

Stephen Davis

Mr. Stephen R. Davis is President, Chief Executive Officer, Chief Financial Officer, Director of the Company. Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry and more than 20 years of experience on the boards of directors of publicly held biopharmaceutical companies. He joined ACADIA in July 2014 as Executive Vice President, Chief Financial Officer and Chief Business Officer and was appointed Interim Chief Executive Officer in March 2015. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc., and in numerous executive roles at Neurogen Corporation, including Chief Executive Officer. Mr. Davis currently serves on the Board of Directors of Bellicum Pharmaceuticals, Inc. He also recently served on the Boards of directors of Synageva BioPharma Corp., Heron Therapeutics, and Furiex Pharmaceuticals, Inc. Early in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.

Glenn Baity

Mr. Glenn F. Baity is Executive Vice President, General Counsel, Secretary of ACADIA Pharmaceuticals Inc. He was Vice President, General Counsel, Secretary of ACADIA Pharmaceuticals Inc. From February 2000 until joining us, Mr. Baity was a senior associate at Cooley LLP in their San Diego office, working with a variety of public and private companies on transactional matters, including M&A, financings, compensation and equity matters, and corporate governance. Prior to joining Cooley, Mr. Baity was an associate in the San Francisco office of Brown & Wood LLP (now Sidley Austin LLP) working primarily on public financings for established companies while representing bulge bracket underwriters, such as Goldman Sachs, Merrill Lynch and Morgan Stanley. Mr. Baity received a J.D. from the University of California, Los Angeles and received a B.A. from the University of California, Berkeley.

Terrence Moore

Mr. Terrence O. Moore is the Executive Vice President, Chief Commercial Officer of ACADIA Pharmaceuticals Inc., with effect from August 19, 2013. Mr. Moore has more than 25 years of experience as a senior member of sales and marketing teams at several pharmaceutical companies. He has made key contributions to the building of multi-billion dollar brands in the CNS field, including Prozac®, Zyprexa®, Risperdal®, and Effexor XR®. Prior to joining us, Mr. Moore was a Principal of Cooke-Moore Consulting and, before founding that firm, served as Vice President at Transcept Pharmaceuticals, where he was responsible for commercial strategy, business development, and commercial alliance activities. Previously, Mr. Moore served as Vice President, U.S. Head of Neuroscience Marketing at Organon BioSciences and was responsible for the creating and building its Neuroscience Business Unit. He also served as Vice President, U.S. Marketing, Effexor XR®, as well as Vice President, Global Strategy Depression Portfolio at Wyeth Pharmaceuticals. Earlier, Mr. Moore held senior management positions at Johnson & Johnson, where he helped to launch Risperdal® for additional indications in the U.S., and at Eli Lilly, where he held various sales and marketing roles over 14 years, including Zyprexa® Brand Manager. Mr. Moore holds a B.S. in Pharmacy from the University of Florida, a B.A. in Chemistry from the University of South Florida and has completed executive development programs at the Kellogg School of Management and Wharton School of Business.

Srdjan Stankovic

Dr. Srdjan (Serge) Stankovic, M.D., M.S.P.H., is Executive Vice President, Head - Research and Development of the Company. Dr. Stankovic has built and led multidisciplinary teams for small molecules and biologics in therapeutic areas including neurology, psychiatry, oncology, cardiology and pain . He has led teams to achieve approvals of KEPPRA ® , FENTORA ® , TREANDA ® , NUVIGIL ® and ARISTADA™. Dr. Stankovic most recently served as Senior Vice President of Clinical Development and Medical Affairs at Alkermes plc. from 2013 to 2015. Prior to Alkermes, he held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals Ltd. He was appointed to this role following Teva's acquisition of Cephalon, Inc. where he served as Senior Vice President, Worldwide Clinical Research. Dr. Stankovic also held executive positions in research and development at Forest Laboratories, Inc., Neurogen Corporation, Johnson and Johnson, and UCB. Dr. Stankovic received his M.D. from the University of Belgrade and holds a Master of Science in Public Health from the University of Alabama at Birmingham.

Julian Baker

Mr. Julian C. Baker is Director of the Company. Mr. Baker serves as a managing partner of Baker Brothers Investments, a fund management company focused on long-term investments in publicly-traded life sciences companies, and which participated in our March 2014 financing as an investor through the following funds (the "Funds"): 667, L.P., Baker Brothers Life Sciences, L.P. and 14159, L.P.

James Daly

Mr. James M. Daly is Director of the Company. Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. During his tenure, he was instrumental in re-accelerating the launch of Jakafi ® and driving sustained growth. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for ten years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen's Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp ® , Neulasta ® , Vectibix ® , Nplate ® , Xgeva ® and Prolia ® . Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair ® . He currently serves on the Board of Directors of Chimerix Inc. Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo, The State University of New York.

Edmund Harrigan

Dr. Edmund P. Harrigan, M.D., is Director of the Company. Dr. Harrigan is a board-certified neurologist with 25 years of executive leadership experience in the pharmaceutical industry, most recently serving as Senior Vice President, Worldwide Safety and Regulatory at Pfizer Inc. Dr. Harrigan's executive roles at Pfizer span over 18 years and across multiple functions. He served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer from 2012 to 2015, where he led a 3,500-person team in 80 countries that was responsible for collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Dr. Harrigan's previous executive leadership roles at Pfizer include serving as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain. Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years. He currently serves on the Board of Directors of Karuna Pharmaceuticals Inc. Dr. Harrigan earned his B.A. degree in Chemistry from St. Anselm College and holds an M.D. from the University of Massachusetts at Worcester. He also attended the Brain Research Institute at the University of California, Los Angeles

Laura Brege

Ms. Laura A. Brege is Independent Director of ACADIA Pharmaceuticals, Inc. Currently, Ms. Brege is Chief Executive Officer and President of Nodality, Inc., a private company focused on innovative personalized medicine. Prior to joining Nodality in September 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., from June 2006 to December 2011, including Executive Vice President and Chief Operating Officer. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies, since 1999. Prior to Red Rock, she was the Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of public companies Aratana Therapeutics, Inc., Delcath Systems, Inc., Pacira Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc. and Dynavax Technologies Corporation. The NCG Committee believes that Ms. Brege’s industry background, including her extensive experience as an officer of public companies in the biotechnology industry, position her to make an effective contribution to the Board and the Audit Committee. In addition, her past financial experience and current knowledge of financing trends are extremely valuable to the Board when considering financing strategies for the Company. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. During the past five years, Ms. Brege also served on the board of Angiotech Pharmaceuticals, Inc., a public company.

Daniel Soland

Mr. Daniel B. Soland is Independent Director of the Company. Mr. Soland was employed at ViroPharma, Inc., a pharmaceutical company, from 2006 until its acquisition by Shire Plc in early 2014, most recently serving as Senior Vice President and Chief Operating Officer of ViroPharma. While at ViroPharma, Mr. Soland helped build ViroPharma’s organizational and commercial infrastructure that resulted in an 11-fold increase in ViroPharma’s share price during his tenure. Previously, as President of Chiron Vaccines, Mr. Soland helped engineer a turnaround that contributed to Chiron Corporation’s acquisition by Novartis AG. Prior to Chiron, he was President and CEO of Epigenesis Pharmaceuticals, Inc. and Vice President and Director, Worldwide Marketing Operations for GlaxoSmithKline Biologicals. Earlier in his career, Mr. Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux’s Connaught Laboratories. He holds a B.S. in Pharmacy degree from the University of Iowa. He currently serves on the boards of Tarsa Therapeutics, Inc. and DBV Technologies SA

Lisa Barthelemy

Basic Compensation